WAM
LSBPW

Wolverine Asset Management’s LakeShore Biopharma Warrants LSBPW Stock Holding History

Wolverine Asset Management’s Portfolio LSBPW Stock Details LSBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,200
Closed -$45 – 1912
2023
Q4 		$45 Buy
+1,200
New +$40 ﹤0.01% 1753

Other funds holding LSBPW

AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
VAM
Valliance Asset Management Central, Hong Kong $122M AUM 362.1% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
BP
BFAM Partners Northpoint, Hong Kong, Hong Kong $44K AUM 8.69% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
QGA
Q Global Advisors Fort Worth, Texas $113M AUM 20.91% 1-Year Est. Return

Wolverine Asset Management's LSBPW Position: Q1 2024 in Review

Wolverine Asset Management sold out of LakeShore Biopharma Warrants (LSBPW) in Q1 2024, closing a stake of 1,200 shares — an estimated $45 sold.

Wolverine Asset Management first reported a position in LSBPW in Q4 2023 and held it in 1 quarter. The position peaked at $45 in Q4 2023. 25 funds tracked by Wall St. Rank hold LSBPW as of Q1 2024.

  • Wolverine Asset Management reported no remaining LakeShore Biopharma Warrants position as of Q1 2024 after selling out during the quarter.
  • Wolverine Asset Management sold 1,200 LakeShore Biopharma Warrants shares in Q1 2024, an estimated $45.
  • Wolverine Asset Management first reported a position in LakeShore Biopharma Warrants in Q4 2023 and held it in 1 quarter.
  • Wolverine Asset Management's LakeShore Biopharma Warrants position peaked at $45 in Q4 2023.
  • 25 funds tracked by Wall St. Rank held LakeShore Biopharma Warrants as of Q1 2024.

Based on Wolverine Asset Management's 13F filing for Q1 2024, filed 13 May 2024.